Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
US8288342B2 · kind B2 · utility
0Cited by
14References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 2009 |
| Grant date | Oct 16, 2012 |
| Priority date | — |
| Expiry date | Jan 17, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.